StockData
Vivos Therapeutics, Inc. logo

Vivos Therapeutics, Inc. (VVOS) stock

VVOSNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 3/30
$0.05−0.00 (-5.10%)

Close on Nov 20, 2026Market cap $1.09MP/E –Yield –

Vivos Therapeutics free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Vivos Therapeutics's free cash flow for the twelve months ending Jun 30, 2026 was -$19.01M. For fiscal 2025 it was -$17.60M. The highest annual figure on record is -$5.52M in fiscal 2019.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$17.60M–
FY2024Dec 31, 2024-$13.26M–
FY2023Dec 31, 2023-$12.75M–
FY2022Dec 31, 2022-$20.51M–
FY2021Dec 31, 2021-$18.13M–
FY2020Dec 31, 2020-$5.80M–
FY2019Dec 31, 2019-$5.52M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$3.56M–
Q1 FY2026Mar 31, 2026-$6.03M–
Q4 FY2025Dec 31, 2025-$5.34M–
Q3 FY2025Sep 30, 2025-$4.08M–
Q2 FY2025Jun 30, 2025-$4.27M–
Q1 FY2025Mar 31, 2025-$3.92M–
Q4 FY2024Dec 31, 2024-$3.11M–
Q3 FY2024Sep 30, 2024-$4.38M–
Q2 FY2024Jun 30, 2024-$3.11M–
Q1 FY2024Mar 31, 2024-$2.67M–
Q4 FY2023Dec 31, 2023-$2.91M–
Q3 FY2023Sep 30, 2023-$2.95M–
Q2 FY2023Jun 30, 2023-$3.10M–
Q1 FY2023Mar 31, 2023-$3.78M–
Q4 FY2022Dec 31, 2022-$3.20M–
Q3 FY2022Sep 30, 2022-$5.94M–
Q2 FY2022Jun 30, 2022-$5.17M–
Q1 FY2022Mar 31, 2022-$6.20M–
Q4 FY2021Dec 31, 2021-$4.50M–
Q3 FY2021Sep 30, 2021-$4.50M–
Q2 FY2021Jun 30, 2021-$5.01M–
Q1 FY2021Mar 31, 2021-$4.12M–
Q4 FY2020Dec 31, 2020-$3.71M–
Q3 FY2020Sep 30, 2020-$686.45K–
Q2 FY2020Jun 30, 2020-$958.40K–
Q1 FY2020Mar 31, 2020-$442.11K–

More Vivos Therapeutics figures

See a number that looks wrong?